Key facts
- It has raised $1.6M; the latest was Later Stage VC ($1.1M) in Sep 2025.
- Notable investors include Parent Project Muscular Dystrophy, The Jain Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kinea Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Kinea Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kinea Bio
Operator of a biotechnology company intended to accelerate the development of next-generation AAV-based gene therapies to treat neuromuscular diseases. The company offers novel targeting and gene regulation technologies, such as advanced engineered tissue modeling capabilities and splicing strategies, enabling patients to address the most critical challenges facing the field and the landscape of gene therapy.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2020
- Employees
- 6
- Website
- kineabio.com/
- Ownership
- Privately Held (backing)
Kinea Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kinea Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kinea Bio in its N-PORT filings yet. We sweep new filings monthly.